Nonconvulsive Status Epilepticus in Elderly Patients Receiving SSRIs;Euglycemic Diabetic Ketoacidosis Associated with Canagliflozin Use in a Type 1 Diabetic Patient;Duloxetine-Induced Galactorrhea;Canagliflozin-Associated Severe Hypercalcemia and Hypernatremia;Vemurafenib-Induced Fanconi Syndrome
Restricted accessResearch articleFirst published online October, 2015
Nonconvulsive Status Epilepticus in Elderly Patients Receiving SSRIs;Euglycemic Diabetic Ketoacidosis Associated with Canagliflozin Use in a Type 1 Diabetic Patient;Duloxetine-Induced Galactorrhea;Canagliflozin-Associated Severe Hypercalcemia and Hypernatremia;Vemurafenib-Induced Fanconi Syndrome
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers.
Get full access to this article
View all access options for this article.
References
1.
TaniguchuiG, MiyajimaM, WatanabeM, Nonconvulsive status epilepticus in the elderly associated with newer antidepressants used at therapeutic doses: A report of three cases. Epilep Behav Case Rep.2015;3:8–11.
2.
St HilaireR, CostelloH.Prescriber beware: Report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication. Am J Emerg Med.2015;33:604.e3–604.e4.
3.
DemirciS, UnubolM, DemirciK.Galactorrhea with normal prolactin levels associated with duloxetine. J Clin Psychopharmacol.2015;35(3):346–347.
4.
KaurA, WintersS.Severe hypercalcemia and hyponatremia in a patient treated with canagliflozin [published online ahead of print June 5, 2015]. Endocrinol Diabetes Metab Case Rep.2015;2015:150042.10.1530/EDM-15-0042.
5.
DeniaD, FranckN, FichelF, Fanconi syndrome induced by vemurafenib: A new renal adverse event. JAMA Derm.2015;151(4):453–454.
